CAR-T therapy alters synthesis of platelet-activating factor in multiple myeloma patients
Open Access
- 9 June 2021
- journal article
- letter
- Published by Springer Science and Business Media LLC in Journal of Hematology & Oncology
- Vol. 14 (1), 1-6
- https://doi.org/10.1186/s13045-021-01101-6
Abstract
The chimera antigen receptor (CAR) T cell therapy is a novel and potential targeted therapy and has achieved satisfactory efficacy in patients with relapsed or refractory multiple myeloma (MM) in recent years. However, cytokine release syndrome (CRS) and clinical efficacy have become the major obstacles which limit the application of CAR-T in clinics. To explore the potential biomarkers in plasma for evaluating CRS and clinical efficacy, we performed metabolomic and lipidomic profiling of plasma samples from 17 relapsed or refractory MM patients received CAR-T therapy. Our study showed that glycerophosphocholine (GPC), an intermediate of platelet-activating factor (PAF)-like molecule, was significantly decreased when the participants underwent CRS, and the remarkable elevation of lysophosphatidylcholines (lysoPCs), which were catalyzed by lysoPC acyltransferase (LPCAT) was a distinct metabolism signature of relapsed or refractory MM patients with prognostic value post-CAR-T therapy. Both GPC and lysoPC are involved in platelet-activating factor (PAF) remodeling pathway. Besides, these findings were validated by LPCAT1 expression, a key factor in the PAF pathway, associated with poor outcome in three MM GEP datasets of MM. In conclusion, CAR-T therapy alters PAF synthesis in MM patients, and targeting PAF remodeling may be a promising strategy to enhance MM CAR-T therapy.Keywords
Funding Information
- National Natural Science Foundation of China (82073885)
This publication has 12 references indexed in Scilit:
- HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNAJournal of Hematology & Oncology, 2021
- European Myeloma Network perspective on CAR T-Cell therapies for multiple myelomaHaematologica, 2021
- Emerging agents and regimens for multiple myelomaJournal of Hematology & Oncology, 2020
- Multiple myeloma: 2020 update on diagnosis, risk‐stratification and managementAmerican Journal of Hematology, 2020
- Forty Years Since the Structural Elucidation of Platelet-Activating Factor (PAF): Historical, Current, and Future Research PerspectivesMolecules, 2019
- Modulation of inflammatory platelet-activating factor (PAF) receptor by the acyl analogue of PAFJournal of Lipid Research, 2018
- Platelet-activating factor (PAF) receptor as a promising target for cancer cell repopulation after radiotherapyOncogenesis, 2017
- Involvement of platelets in tumor cell metastasisPharmacology & Therapeutics, 2016
- Topical Photodynamic Therapy Induces Systemic Immunosuppression via Generation of Platelet-Activating Factor Receptor LigandsJournal of Investigative Dermatology, 2015
- Glutamine inhibits platelet-activating factor-mediated pulmonary tumour metastasisEuropean Journal of Cancer, 2011